Melbourne, May 2, 2026, 06:10 AEST
CSL Limited bought back 110,004 shares on April 30, a May 1 ASX filing showed, lifting total shares repurchased under its on-market programme to 6.35 million and consideration paid or payable to about A$1.06 billion. The buyback, capped at up to US$750 million, is due to run until June 30.
The filing lands at a raw point for CSL. Reuters reported last week the stock had fallen to its lowest since late August 2017 after the U.S. military scrapped its flu vaccine mandate, with Marc Jocum, senior product and investment strategist at GlobalXETFs, saying the Pentagon move added pressure “at the worst possible time.” Vantage Markets analyst Hebe Chen said the “real issue runs deeper” than one policy shift. Reuters
Buybacks can dull a sell-off. They do not fix one. An on-market buyback is a company repurchasing its own shares through the exchange, often to return capital and reduce the share count, but CSL is still being judged on demand for plasma therapies, vaccine volumes and whether earnings can recover fast enough.
CSL’s February result set that bar. The company reported first-half revenue of US$8.3 billion, down 4% at constant currency, underlying NPATA of US$1.9 billion, down 7%, and reported net profit after tax of US$401 million, down 81%; NPATA is net profit after tax before amortisation and major one-off items. Chief Financial Officer Ken Lim said CSL was “not satisfied with our performance” and pointed to an “ambitious growth plan” for the second half.
But the risk is that the second half has to carry too much weight. Citi analysts said investors were likely to focus on whether CSL could deliver the sharp turnaround implied by guidance, with Behring left to “do most of the heavy lifting” while Seqirus and Vifor faced their own pressures. Reuters
The U.S. flu vaccine decision also puts CSL in a tougher competitive patch. Reuters reported that Sanofi, GSK and AstraZeneca were among vaccine makers exposed to the policy backdrop alongside CSL Seqirus, after Defense Secretary Pete Hegseth said service members would no longer be required to get flu shots.
CSL’s counterweight is plasma manufacturing. In March, the company broke ground on a US$1.5 billion expansion in Kankakee, Illinois, saying the site should be operational by 2031 and create at least 300 pharmaceutical roles. Chief Executive Gordon Naylor said the project “strengthens this key hub” in CSL’s supply network, while Chief Operating Officer Mary Oates said the work should lift protein yield from each gram of plasma collected. Global Newsroom | CSL
Tariffs remain another policy variable, though CSL has sought to narrow the concern. In an April 7 filing, the company said its initial view was that most U.S. product sales would not be subject to planned U.S. pharmaceutical tariffs, while its U.S. Fluad product is made in the UK, where the tariff rate was then 10% and expected to fall to zero.
CSL is no small single-product drugmaker. Its units span CSL Behring in plasma products, gene therapies and recombinants, CSL Seqirus in mostly influenza-related vaccines, and CSL Vifor in iron deficiency and nephrology; LSEG data carried by Reuters lists its main markets as Australia, the United States, Germany, the United Kingdom, Switzerland and China.
The next scheduled hard test is still some distance away. CSL’s financial calendar lists its full-year results and final dividend announcement for Aug. 18, leaving daily buyback notices, U.S. policy headlines and any trading updates to do most of the talking in the meantime.
